Several phase I and II clinical trials have demonstrated the efficacy of crizotinib in advanced-stage, ALK-positive NSCLC patients, resulting in the accelerated approval of crizotinib by the FDA in August 2011[6], [7]. This evidence concerns the gene ALK and non-small cell lung carcinoma.